LGD4033 (Ligandrol)120 tabs 2mg/tab
A Natural Sarms Product.
LGD 4033 is a sarm.(selective Androgen Receptor Modulator).
LGD 4033 is extremely well known and popular among all types of athletes, Due to its ability to increase lean muscle tissue without the side effects that come with steroids.
LGD 4033 is one of the strongest sarms developed.
LGD4033 is a non-steroidal sarm that binds to Androgen receptors with high affinity and selectivity.
LGD 4033 was originally developed by Ligand Pharmaceuticals for treatment for conditions associated with muscle wasting and Bone deterioration such as osteoporosis.
LGD has been shown to increase bone mineral density.
LGD 4033 has a definite anabolic effect when it comes to building muscle and anti resorptive and anabolic activity in bone, and strong selectivity for muscle vs the prostate.
Users can expect increase lean muscle mass, improved strength and stamina, while also reducing body fat do to binding so strongly to the Androgen receptor.
LGD is very versatile and can be used to lean bulk,
help maintain your hard earned muscle during a cut, or during a recomp.
LGD 4033 can be ran solo or stacked with other sarms or AAS
I find LGD 4033 is great to run solo or stacked along side your trt inbetween cycles.
LGD 4033 has a 24-36hr half life.
Dosing of 5 -10mg once a day is considered standard.
Although doses upwards of 20mg daily is well tolerated.
Standard Cycle length 8-12 weeks
--------------------------------
The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men
Full text
https://www.ncbi.nlm.nih.gov/m/pubmed/22459616/#
Randomized controlled trialBasaria S, et al. J Gerontol A Biol Sci Med Sci. 2013.
Show full citation
Abstract
BACKGROUND: Concerns about potential adverse effects of testosterone on prostate have motivated the development of selective androgen receptor modulators that display tissue-selective activation of androgenic signaling. LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity. Objectives. To evaluate the safety, tolerability, pharmacokinetics, and effects of ascending doses of LGD-4033 administered daily for 21 days on lean body mass, muscle strength, stair-climbing power, and sex hormones.
METHODS: In this placebo-controlled study, 76 healthy men (21-50 years) were randomized to placebo or 0.1, 0.3, or 1.0 mg LGD-4033 daily for 21 days. Blood counts, chemistries, lipids, prostate-specific antigen, electrocardiogram, hormones, lean and fat mass, and muscle strength were measured during and for 5 weeks after intervention.
RESULTS: LGD-4033 was well tolerated. There were no drug-related serious adverse events. Frequency of adverse events was similar between active and placebo groups. Hemoglobin, prostate-specific antigen, aspartate aminotransferase, alanine aminotransferase, or QT intervals did not change significantly at any dose. LGD-4033 had a long elimination half-life and dose-proportional accumulation upon multiple dosing. LGD-4033 administration was associated with dose-dependent suppression of total testosterone, sex hormone-binding globulin, high density lipoprotein cholesterol, and triglyceride levels. follicle-stimulating hormone and free testosterone showed significant suppression at 1.0-mg dose only. Lean body mass increased dose dependently, but fat mass did not change significantly. Hormone levels and lipids returned to baseline after treatment discontinuation.
CONCLUSIONS: LGD-4033 was safe, had favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen. Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.
PMID
22459616 [Indexed for MEDLINE] PMCID
PMC4111291
Full text
Free PMC article
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111291/
Full text at journal site
https://academic.oup.com/biomedgerontol ... /87/548321
